InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,408.42
(
-1.73%
)
US TECH 100
17,870.94
(
-3.09%
)
Dow Jones
40,345.41
(
-1.01%
)
Brent Oil
70.89
(
0.00%
)
Bitcoin
54,483.30
(
0.57%
)
Post# of 253058
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120392
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 35907

Friday, 10/20/2006 1:53:05 PM

Friday, October 20, 2006 1:53:05 PM

Post# of 253058
SGP’s HCV franchise is generating sales at a $1.3B annual rate despite its consisting of:

1. A second-best product in its class (Peg-Intron);
2. An obsolete product (Intron-A); and
3. A product whose patent has run out (Rebetol).

They must have some good sales reps.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up